ALB's Materials Website: www.albmaterials.com
Home > Products > Antibody Drug Conjugates > ADCs Cytotoxin > MMAE | Monomethyl Auristatin E | CAS Number: 474645-27-7 | Tubulin-Binders

MMAE | Monomethyl Auristatin E | CAS Number: 474645-27-7 | Tubulin-Binders

Product Name Monomethyl Auristatin E | MMAE Price ($) $388/20mg
Inquiry
Synonyms MMAE; Vedotin; HM-297C-22; N-Methyl-L-valyl-N-[(1S,2R)-4-[(2S)-2-[(1R,2R)-3-[[(1R,2S)-2-hydroxy-1-methyl-2-phenylethyl]amino]-1-methoxy-2-methyl-3-oxopropyl]-1-pyrrolidinyl]-2-methoxy-1-[(1S)-1-methylpropyl]-4-oxobutyl]-N-methyl-L-valinamide
Item No. ADCs-T0004 CAS Number 474645-27-7
Molecular Formula C39H67N5O7 Molecular Weight 717.98
Supplier ALB Technology Limited Purity 98%
COA COA of MMAE | Monomethyl Auristatin E | CAS Number: 474645-27-7 | Tubulin-Binders MSDS MSDS of MMAE | Monomethyl Auristatin E | CAS Number: 474645-27-7 | Tubulin-Binders
Chemical Structure

Inquiry Button

Download SDF file: MMAE_Monomethyl-Auristatin-E_cas-474645-27-7.sdf

Difference between MMAE & MMAF & Vc-MMAE

 

Monomethyl auristatin E (MMAE) and Monomethyl auristatin F (MMAF) are both tubulin polymerization inhibiter.They are synthetic derivatives of dolastatin 10 and functions as a potent antimitotic agent by inhibiting tubulin polymerization. Monomethyl auristatin E, have been conjugated to antibodies via cleavable linkers (MC-vc-PAB) through internal cysteines.It should be noted that MMAE and MMAF are fully synthetic drugs, which may confer them a price advantage compared to other ADC payloads.

The major difference between MMAE and MMAF is that MMAF possesses a phenylalanine at the C-terminus, contributing to membrane impermeability. It was possible to derivatize MMAF at the amine terminus with a noncleavable linker without any loss of activity, which was not the case for the MMAE analog. The ADC SGN-35 (brentuximab vedotin) composed of MMAE which is bound to a chimeric anti-CD30 monoclonal antibody through a cleavable valine–citruline linker had good clinical results in multiple phase I, II, and III clinical trials. On 19 August 2011, the US Food and Drug Administration (FDA) granted accelerated approval for the use of brentuximab vedotin in relapsed Hodgkin lymphoma and relapsed systemic anaplastic large cell lymphoma under the brand name Adcetris. Currently, brentuximab vedotin is the only FDA-approved ADC and the first approved drug for treating Hodgkin lymphoma in 30 years. The other promising auristatin derivative MMAF entered as a MMAF-ADC by now at least three phase I clinical trials: in subjects with renal cell carcinoma (RCC) of clear cell or papillary histology (AGS-16C3F, AGS-16M8F) and in subjects with CD70-positive non-Hodgkin lymphoma or RCC (SGN-75).

 

MMAE related articles:

Products

A Quick Inquiry

A Quick Inquiry

Contact Us

Company

Newsletter Subscribe